{"title":"Metabolic Health","description":null,"products":[{"product_id":"retatrutide","title":"Retatrutide","description":"\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide Research Peptide (30 mg and 60 mg Vials)\u003c\/span\u003e\u003c\/h1\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"180\"\u003e\n\u003ccol width=\"444\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlternate name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLY3437943\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound class\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTriple GIP, GLP-1 and glucagon receptor agonist (acylated peptide); investigational\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSealed research vial; one product with two strength options (physical form stated on the label and COA)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStrength(s)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e30 mg or 60 mg per vial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eH-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(C20 diacid-γGlu-AEEA)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (39 residues; Aib = 2-aminoisobutyric acid; αMeLeu = alpha-methyl-L-leucine)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular formula\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eC221H342N46O68 (PubChem, computed)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e4731 g\/mol (PubChem, computed)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCAS number\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e2381089-83-2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStated per lot on the Certificate of Analysis\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eManufacturer\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePEPTYVA, Mexico\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is retatrutide?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide (LY3437943) is an investigational 39-residue peptide developed by Eli Lilly that acts as an agonist at three receptors: GIP, GLP-1 and glucagon. PEPTYVA supplies it as one product in 30 mg and 60 mg vials for laboratory research use only. It is not an approved medicine in any country.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe FDA Global Substance Registration System describes its sequence with two Aib residues, an alpha-methyl leucine and a lysine linked to a C20 fatty diacid through a gamma-glutamyl and short ethylene glycol spacer.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is retatrutide studied in research?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide is studied as a triple hormone receptor agonist. Its three-receptor profile makes it a reference compound for comparing single (GLP-1), dual (GIP and GLP-1) and triple (GIP, GLP-1 and glucagon) receptor agonism in one molecular family.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eTargets: GIP, GLP-1 and glucagon receptors\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eStructure: 39 residues, C-terminal amide, C20 fatty diacid on lysine 17\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eTypical research topics: receptor pharmacology, glycemic regulation, body weight regulation in controlled studies\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat does the current evidence show?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eControlled human studies exist, and the molecule remains investigational. A phase 2 trial (New England Journal of Medicine, 2023) randomized 338 adults with obesity, or with overweight and a weight-related condition, to retatrutide or placebo for 48 weeks. Gastrointestinal events were the most common adverse events, and heart rate increases peaked at 24 weeks and declined afterward.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe phase 3 TRIUMPH-1 trial (New England Journal of Medicine, 2026) randomized 2,339 adults with obesity and without diabetes for 80 weeks, with body weight, knee osteoarthritis pain and sleep apnea endpoints. It met its primary endpoints, and gastrointestinal events were again the most common adverse events. In July 2026 Eli Lilly reported that five phase 3 studies had met their primary endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does retatrutide differ from tirzepatide?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTirzepatide activates GIP and GLP-1 receptors and is approved within branded medicines. Retatrutide adds glucagon receptor activity and has no approval. Both are 39-residue acylated peptides that share the same C-terminal segment, Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, which makes them close comparators in receptor research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhy are 30 mg and 60 mg listed as one product?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe two strengths are variants of the same product. The molecule and specifications do not change; only the amount per vial differs. Each vial label shows its strength, lot number and expiry date.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is each retatrutide vial documented?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEach vial is linked to its Certificate of Analysis by the PEPTYVA lot number. A COA typically reports identity by mass spectrometry, purity by HPLC, appearance and test dates. Because retatrutide is investigational and has no approved reference product, lot-level identity data are the main way to confirm what the vial contains.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is the regulatory status of retatrutide?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide is not approved by the FDA, COFEPRIS or any other regulator. Eli Lilly stated in July 2026 that it plans to submit retatrutide for US approval in the first quarter of 2027. This PEPTYVA vial is research material only, and any future approval would belong to the sponsor's branded product.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eDocumentation\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEach vial carries a PEPTYVA lot number, strength and expiry date. The Certificate of Analysis for that lot can be requested through our contact page and typically lists identity, purity, appearance and test dates. See Quality \u0026amp; Documentation for how to read a COA.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eStorage and handling\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eKeep the unopened vial sealed in its original packaging, protected from light and heat, at the storage temperature printed on the PEPTYVA label. Check the strength, lot number and expiry date on arrival, and do not use material past the expiry date shown on the label.\u003c\/span\u003e\u003c\/p\u003e","brand":"peptides ","offers":[{"title":"30 mg \/ B","offer_id":46525689921732,"sku":null,"price":5260.0,"currency_code":"MXN","in_stock":true},{"title":"60 mg \/ B","offer_id":46525689954500,"sku":null,"price":8060.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/RT30_Retatrutide.jpg?v=1792788712"},{"product_id":"tirzepatide","title":"Tirzepatida","description":"\u003cdiv class=\"markdown markdown-main-panel md-content enable-luminous-fast-follows enable-updated-hr-color stronger tutor-markdown-rendering\" id=\"model-response-message-contentr_2eb65a1e74c1dcb3\" dir=\"ltr\"\u003e\n\u003cdiv\u003e\u003cb\u003eTirzepatida (TR Series) — Research Peptide\u003c\/b\u003e\u003c\/div\u003e\n\u003cbr\u003e\n\u003cdiv\u003e\u003cb\u003eProduct Overview\u003c\/b\u003e\u003c\/div\u003e\n\u003cbr\u003e\n\u003cdiv\u003eTirzepatida is a synthetic peptide engineered as a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This high-purity, lyophilized reagent is widely utilized in scientific laboratory settings for metabolic receptor profiling, signaling path investigations, and \u003ci\u003ein vitro\u003c\/i\u003e assay development.\u003c\/div\u003e\n\u003cbr\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTechnical Specifications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDetails\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cb\u003eActive Compound\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eTirzepatida (GLP-1 \/ GIP Dual Agonist)\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cb\u003eCAS Number\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003e2023788-19-2\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cb\u003eSequence\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eTyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 diacid linker)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cb\u003eMolecular Formula\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cspan class=\"math-inline\"\u003e$\\text{C}_{225}\\text{H}_{348}\\text{N}_{48}\\text{O}_{68}$\u003c\/span\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cb\u003eMolecular Weight\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003e4813.53 g\/mol\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cb\u003ePurity\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003e≥98.0% (Verified by HPLC)\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003e\u003cb\u003ePhysical Format\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eSterile, lyophilized white powder in sealed glass vials\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cb\u003eKey Features \u0026amp; Quality Assurance\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDual Receptor Targeting:\u003c\/b\u003e Formulated specifically to assess dual GIP and GLP-1 receptor activation kinetics in cell-based models.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eHigh Analytical Purity:\u003c\/b\u003e Every batch is tested using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to verify molecular weight and sequence integrity.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eLyophilized Matrix:\u003c\/b\u003e Freeze-dried under clean conditions to ensure long-term stability and structural integrity during transit.\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cb\u003eStorage \u0026amp; Handling Guidelines\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReconstitution:\u003c\/b\u003e Intended for reconstitution with sterile analytical solvents or bacteriostatic water inside a laminar flow hood.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eStorage (Unopened):\u003c\/b\u003e Keep dry and refrigerated at \u003cb\u003e2°C to 8°C\u003c\/b\u003e for short-term shelf life, or frozen at \u003cb\u003e-20°C\u003c\/b\u003e for extended preservation.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eStorage (Reconstituted):\u003c\/b\u003e Store liquid aliquots at \u003cb\u003e2°C to 8°C\u003c\/b\u003e and use within standard laboratory testing protocols. Minimize freeze-thaw cycles.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"peptides ","offers":[{"title":"30 mg \/ A","offer_id":46525708665028,"sku":null,"price":5260.0,"currency_code":"MXN","in_stock":true},{"title":"40 mg \/ A","offer_id":47109061902532,"sku":null,"price":5660.0,"currency_code":"MXN","in_stock":true},{"title":"60 mg \/ A","offer_id":47109061935300,"sku":null,"price":6060.0,"currency_code":"MXN","in_stock":true},{"title":"80 mg \/ A","offer_id":47109061968068,"sku":null,"price":6660.0,"currency_code":"MXN","in_stock":true},{"title":"100 mg \/ A","offer_id":47109062000836,"sku":null,"price":7260.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/Tirzepatida30mg.jpg?v=1792951231"},{"product_id":"semaglutide","title":"Semaglutida","description":"\u003ch1 dir=\"ltr\"\u003e\u003cstrong\u003eSemaglutide 10 mg Research Peptide\u003c\/strong\u003e\u003c\/h1\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"180\"\u003e\n\u003ccol width=\"444\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlternate name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eNN9535; NNC 0113-0217\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound class\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 receptor agonist (acylated GLP-1 analog peptide)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSealed research vial (physical form stated on the label and COA)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStrength(s)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e10 mg per vial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eH-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 diacid-γGlu-AEEA-AEEA)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (31 residues; Aib = 2-aminoisobutyric acid; AEEA = aminoethoxyethoxyacetyl spacer)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular formula\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eC187H291N45O59\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e4113.58 g\/mol\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCAS number\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e910463-68-2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStated per lot on the Certificate of Analysis\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eManufacturer\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePEPTYVA, Mexico\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is semaglutide?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1). This product is a 10 mg vial of semaglutide made by PEPTYVA in Mexico and sold for laboratory research use only. It is not a medicine and is not intended for human or veterinary use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe molecule shares 94% sequence homology with human GLP-1. According to the FDA label for Ozempic, it is modified at position 8 for stability against enzymatic breakdown, and a lysine side chain is linked to a C18 fatty diacid through a hydrophilic spacer. PubChem attributes its long half-life of about 168 hours to albumin binding.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is semaglutide studied in research?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide is studied as a selective GLP-1 receptor agonist. It binds and activates the GLP-1 receptor, the target of the native hormone, which makes it a reference compound for incretin signaling and for long-acting peptide design.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eTarget: GLP-1 receptor (selective agonist)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eStructure: Aib at position 8 (GLP-1 numbering), acylated lysine carrying a C18 fatty diacid\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eTypical research topics: incretin receptor pharmacology, glucose regulation, energy balance models\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eReference use: comparator for dual and triple receptor agonists such as tirzepatide and retatrutide\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat does the current evidence show?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eControlled human evidence for semaglutide is extensive, but it belongs to specific branded medicines. In the STEP 1 trial (New England Journal of Medicine, 2021), 1,961 adults with overweight or obesity and without diabetes were randomized to semaglutide or placebo for 68 weeks, with lifestyle intervention in both groups. The trial met both coprimary body weight endpoints. Nausea and diarrhea were the most common adverse events.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThese data describe approved branded products used under regulated conditions. They do not describe this research vial, whose identity and purity are documented per lot for laboratory work.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does semaglutide differ from tirzepatide?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide acts on one receptor, the GLP-1 receptor. Tirzepatide is built on the GIP sequence and activates both GIP and GLP-1 receptors, according to its FDA label. Retatrutide, which is still investigational, adds glucagon receptor activity. All three carry fatty diacid side chains, so they are often compared in receptor pharmacology work.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is each semaglutide vial documented?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEvery vial carries a PEPTYVA lot number and expiry date that link it to a Certificate of Analysis. A COA typically reports identity, usually by mass spectrometry against the expected molecular weight of 4113.58 g\/mol, purity by HPLC, appearance and test dates. Matching the lot number on the vial to the COA before laboratory work is the simplest traceability check.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is the regulatory status of semaglutide?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eApproval belongs to specific branded products, not to the molecule in general. In the United States, the FDA has approved Ozempic and Rybelsus for adults with type 2 diabetes and Wegovy for chronic weight management and cardiovascular risk reduction in defined adults. In Mexico, a 2023 COFEPRIS notice confirms that Ozempic holds a sanitary registration for adults with type 2 diabetes and requires a medical prescription. None of these approvals extends to this PEPTYVA research vial.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eDocumentation\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEach vial carries a PEPTYVA lot number and expiry date. The Certificate of Analysis (COA) for that lot can be requested before or after ordering; a COA typically lists identity, purity, appearance, lot number and test dates. See Quality \u0026amp; Documentation for how to read each section.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eStorage and handling\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eKeep the unopened vial sealed in its original packaging, protected from light and heat, at the storage temperature printed on the PEPTYVA label. Check the strength, lot number and expiry date on arrival, and do not use material past the expiry date shown on the label.\u003c\/span\u003e\u003c\/p\u003e","brand":"Peptides Vallarta","offers":[{"title":"10 mg \/ A","offer_id":47106181988548,"sku":"PV-SEMA-10MG","price":5660.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/Semaglutida10mg.jpg?v=1792952941"},{"product_id":"sema-cag","title":"Sema+Cag","description":"\u003ch1 dir=\"ltr\"\u003e\u003cstrong\u003eSema+Cag (Semaglutide + Cagrilintide) 5 mg\/5 mg Research Peptide\u003c\/strong\u003e\u003c\/h1\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"180\"\u003e\n\u003ccol width=\"444\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlternate name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide + cagrilintide (Novo Nordisk develops this pairing as CagriSema; this vial is not CagriSema)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound class\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 receptor agonist (semaglutide) plus long-acting amylin analog (cagrilintide)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSealed research vial containing both peptides (physical form stated on the label and COA)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStrength(s)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e5 mg semaglutide + 5 mg cagrilintide per vial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 diacid-γGlu-AEEA-AEEA)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (31 residues). Cagrilintide: C20 diacid-γGlu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (37 residues, disulfide bridge between the two cysteines)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular formula\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide C187H291N45O59; cagrilintide C194H312N54O59S2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide 4114 g\/mol; cagrilintide 4409 g\/mol (PubChem, computed)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCAS number\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide 910463-68-2; cagrilintide 1415456-99-3\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStated per lot on the Certificate of Analysis (both components)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eManufacturer\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePEPTYVA, Mexico\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is Sema+Cag?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSema+Cag is a PEPTYVA research vial that combines two peptides: semaglutide 5 mg and cagrilintide 5 mg. It is sold for laboratory research use only and is not a medicine. Semaglutide is a GLP-1 receptor agonist, and cagrilintide is a long-acting amylin analog.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eNovo Nordisk is developing the same pairing as CagriSema, an investigational product. Sema+Cag is not CagriSema. It shares the two active molecules, but it is a separate research material made by PEPTYVA with its own lot documentation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is the semaglutide and cagrilintide pairing studied?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe pairing is studied because it engages two hormone pathways at once: GLP-1 and amylin. Controlled studies compare the combination with each component alone to see how the two pathways interact in glycemic and body weight regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eSemaglutide: selective GLP-1 receptor agonist with a lysine side chain linked to a C18 fatty diacid\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eCagrilintide: long-acting amylin analog acylated at the N-terminus with a C20 fatty diacid\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eTypical research topics: amylin and incretin receptor pharmacology, appetite signaling, glucose regulation\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eStudy design feature: factorial comparisons against each single component and placebo\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat does the current evidence show?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eControlled human studies exist, but the combination is still investigational. REDEFINE 1 (New England Journal of Medicine, 2025) randomized 3,417 adults with overweight or obesity and without diabetes to the combination, semaglutide alone, cagrilintide alone or placebo for 68 weeks. REDEFINE 2 (New England Journal of Medicine, 2025) enrolled 1,206 adults with type 2 diabetes and overweight or obesity for 68 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBoth phase 3 trials met their primary body weight endpoints versus placebo. Gastrointestinal adverse events, such as nausea, vomiting, diarrhea and constipation, were frequent in both trials and mostly mild to moderate. No direct evidence exists for this specific PEPTYVA vial, as opposed to the sponsor's investigational product.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does Sema+Cag differ from semaglutide alone?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide alone acts only on the GLP-1 receptor and is the active ingredient in approved branded medicines. Sema+Cag adds cagrilintide, an amylin analog, and the combination has no regulatory approval. That difference is why semaglutide carries grade A and Sema+Cag carries grade B on this store.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is a two-peptide vial documented?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA combination vial needs documentation for each component. The Certificate of Analysis for a Sema+Cag lot should identify both semaglutide (about 4114 g\/mol) and cagrilintide (about 4409 g\/mol), typically by mass spectrometry, and report purity, typically by HPLC. The lot number and expiry date on the vial link it to that COA.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is the regulatory status of Sema+Cag?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe combination is investigational. Novo Nordisk filed a New Drug Application for CagriSema with the FDA in December 2025 and, in September 2026, said it expects a decision in the fourth quarter of 2026. Any future approval would belong to the sponsor's branded product and would not extend to this PEPTYVA research vial.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eDocumentation\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEach vial carries a PEPTYVA lot number and expiry date. The Certificate of Analysis for that lot can be requested through our contact page; for a two-component vial it should identify both semaglutide and cagrilintide. See Quality \u0026amp; Documentation for how to read a COA.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eStorage and handling\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eKeep the unopened vial sealed in its original packaging, protected from light and heat, at the storage temperature printed on the PEPTYVA label. Check the strength, lot number and expiry date on arrival, and do not use material past the expiry date shown on the label.\u003c\/span\u003e\u003c\/p\u003e","brand":"Peptides Vallarta","offers":[{"title":"5 mg \/ B","offer_id":47106182021316,"sku":"PV-SEMACAG-5MG5MG","price":5060.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/Sema_Cag5mg5mg.jpg?v=1792953753"}],"url":"https:\/\/peptidesvallarta.com\/collections\/metabolic-health.oembed","provider":"Peptides Vallarta","version":"1.0","type":"link"}